Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) closed at $13.1 up 0.23% from its previous closing price of $13.07. In other words, the price has increased by $0.23 from its previous closing price. On the day, 0.79 million shares were traded. AMLX stock price reached its highest trading level at $13.44 during the session, while it also had its lowest trading level at $12.92.
Ratios:
For a deeper understanding of Amylyx Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.70 and its Current Ratio is at 13.70. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On June 24, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $17.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $12.Citigroup initiated its Buy rating on June 17, 2025, with a $12 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 01 ’25 when Bedrosian Camille L sold 6,580 shares for $14.35 per share. The transaction valued at 94,418 led to the insider holds 175,756 shares of the business.
Bedrosian Camille L bought 6,580 shares of AMLX for $94,419 on Dec 01 ’25. On Sep 30 ’25, another insider, Klee Justin B., who serves as the Co-Chief Executive Officer of the company, sold 29,975 shares for $14.38 each. As a result, the insider received 430,952 and left with 3,325,301 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 1438636416 and an Enterprise Value of 1100581376. Its current Enterprise Value per Revenue stands at -1655.01 whereas that against EBITDA is -5.703.
Stock Price History:
The Beta on a monthly basis for AMLX is -0.33, which has changed by 2.1267943 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $16.96, while it has fallen to a 52-week low of $2.60. The 50-Day Moving Average of the stock is -5.81%, while the 200-Day Moving Average is calculated to be 53.57%.
Shares Statistics:
For the past three months, AMLX has traded an average of 1.64M shares per day and 1046720 over the past ten days. A total of 109.77M shares are outstanding, with a floating share count of 91.69M. Insiders hold about 17.00% of the company’s shares, while institutions hold 94.74% stake in the company. Shares short for AMLX as of 1764288000 were 11623612 with a Short Ratio of 7.09, compared to 1761868800 on 10449446. Therefore, it implies a Short% of Shares Outstanding of 11623612 and a Short% of Float of 11.450000000000001.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 8.0 analysts currently analyzing and rating the stock of Amylyx Pharmaceuticals Inc (AMLX).The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.26 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.26 and -$1.79 for the fiscal current year, implying an average EPS of -$1.57. EPS for the following year is -$1.24, with 8.0 analysts recommending between -$0.76 and -$1.64.
